Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Lennar Corporation (LEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Lennar Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Lennar Corporation trades at $84 (market cap $20.25B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Lennar Corporation pays a 2.37% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LEN | |
|---|---|---|
Market Cap | $39.89B | $20.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $142.40 |
52-Week Low | $278.09 | $82.30 |
Enterprise Value | $38.15B | $24.13B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Lennar Corporation (LEN) trades at $84.27, down 0.09% on the day, with the stock showing bearish technical signals despite trading near analyst consensus targets. The homebuilder faces margin pressure with net income declining from $4.6B in 2022 to $2.1B in 2025, though valuation metrics appear attractive with P/E of 13.2 and P/B of 0.9. Recent earnings have consistently missed expectations, with Q2 2026 results showing mixed performance amid challenging housing market conditions.
LEN presents a value opportunity with discounted valuations but faces significant headwinds from declining profitability and housing market volatility. The stock's outlook hinges on execution amid affordability pressures, with analyst consensus leaning bullish (46% buy ratings) but technical indicators suggesting caution. Key risks include ongoing margin compression and macroeconomic sensitivity to interest rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
